These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26302603)

  • 1. Synthetic Biology in the FDA Realm: Toward Productive Oversight Assessment.
    Fatehi L; Hall RF
    Food Drug Law J; 2015; 70(2):339-69, iii-iv. PubMed ID: 26302603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steering vaccinomics innovations with anticipatory governance and participatory foresight.
    Ozdemir V; Faraj SA; Knoppers BM
    OMICS; 2011 Sep; 15(9):637-46. PubMed ID: 21848419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstream oversight assessment for agrifood nanotechnology: a case studies approach.
    Kuzma J; Romanchek J; Kokotovich A
    Risk Anal; 2008 Aug; 28(4):1081-98. PubMed ID: 18627547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms.
    Kuzma J; Najmaie P; Larson J
    J Law Med Ethics; 2009; 37(4):546-86. PubMed ID: 20122100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences.
    Paradise J; Wolf SM; Kuzma J; Kuzhabekova A; Tisdale AW; Kokkoli E; Ramachandran G
    J Law Med Ethics; 2009; 37(4):688-705. PubMed ID: 20122110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leavitt: reforms will improve oversight and openness at FDA.
    FDA Consum; 2005; 39(3):37. PubMed ID: 16127819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulating Black-Box Medicine.
    Price WN
    Mich Law Rev; 2017; 116(3):421-74. PubMed ID: 29240330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology.
    Paradise J; Tisdale AW; Hall RF; Kokkoli E
    J Law Med Ethics; 2009; 37(4):598-624. PubMed ID: 20122103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing an information systems strategy for nursing.
    Callanan KM; Hughes SJ
    Medinfo; 1995; 8 Pt 2():1419. PubMed ID: 8591465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Societal Risk Evaluation Scheme (SRES): Scenario-Based Multi-Criteria Evaluation of Synthetic Biology Applications.
    Cummings CL; Kuzma J
    PLoS One; 2017; 12(1):e0168564. PubMed ID: 28052080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foresight Study on the Risk Governance of New Technologies: The Case of Nanotechnology.
    Read SA; Kass GS; Sutcliffe HR; Hankin SM
    Risk Anal; 2016 May; 36(5):1006-24. PubMed ID: 26332140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RU-486: legal and policy issues confronting the Food and Drug Administration.
    Muhl C
    J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Cost-Benefit Analysis in the Governance of Synthetic Biology.
    Wallach W; Saner M; Marchant G
    Hastings Cent Rep; 2018 Jan; 48 Suppl 1():S70-S77. PubMed ID: 29453841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.